Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study  by Rupp, Richard et al.
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Introduction:  A safe,  effective  dengue  vaccine  that can simultaneously  induce  immunity  to  all  four  dengue
virus  serotypes  (DENV-1–4)  is a public  health  priority.  A  chimeric  tetravalent  dengue  vaccine  (TDV)  based
on an  attenuated  DENV-2  serotype  backbone  was  evaluated  in  healthy,  ﬂavivirus-seronegative  adults.
Methods:  In this  randomized,  multicenter,  Phase  1b  study  conducted  in the  United  States,  the  safety  and
immunogenicity  of TDV  were  evaluated  in 140  participants  aged  18–45  years  in  six dosing  regimen  study
groups.  Participants  were  injected  subcutaneously  on Days  0 and  90;  placebo  (saline)  was  injected  where
appropriate  to maintain  double  blinding.  Three  different  TDV  dosages  (TDV,  a vaccine  in which  TDV-4
had  been increased  three-fold,  and  a  one-tenth  TDV  dose),  and single  or double  dosing  were  evaluated
in  one  and/or  both  arms.  Primary  endpoints  were  solicited  and  unsolicited  adverse  events  (AEs) and
seroconversion  rates  to  DENV-1–4  at Day 120.
Results: The  severity  of all AEs  was  generally  mild.  The  most  common  unsolicited  AEs  were  headache
(52%),  fatigue  (43%)  and  myalgia  (29%).  The  incidence  of  injection  site  pain  ranged  from  29  to  64% and
5  to 52%  among  study  groups  after  the  ﬁrst and  second  doses,  respectively.  At Day  120,  the ranges  of
seroconversion  rates  among  the  groups  were  DEN-1:  84–100%;  DEN-2:  96–100%;  DEN-3:  83–100%;  and
DEN-4:  33–77%.  More  than  80%  of participants  in  each  group  seroconverted  to  at least  three  dengue
serotypes.  Substantial  GMT  increases  from  baseline  were  observed  for DEN-1–3  at  all time  points  from
Day  30  onward;  DEN-4  GMT  increases  were  lower.  Increasing  TDV-4  slightly  increased  DEN-4  GMT,  did
not impact  DEN-2  and  DEN-3  
one-tenth  TDV  dosing  meanin
Conclusions:  All  TDV  doses  an
ﬂavivirus-naive  adults  (Clinica
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. Introduction
Dengue fever is caused by infection with any one of four
erotypes of the dengue ﬂavivirus (DENV-1–4). Symptoms range
rom subclinical disease; to an acute febrile illness with possible
eadache, myalgia, arthralgia, retro-orbital pain, rash and bleed-
ng; to life-threatening dengue hemorrhagic fever or dengue shock
yndrome [1].
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Dengue fever is the most rapidly spreading mosquito-borne
viral disease worldwide [1]. With an estimated 390 million annual
infections globally [2], dengue is a major public health concern
because of the huge burden it exerts on health systems and
economies [3,4]. There is no speciﬁc treatment for dengue; preven-
tion is currently dependent on effective vector control measures.
Dengue vaccines, although in development [5], have not yet been
approved for use.
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Table  1
Composition of study vaccines evaluated in Groups 1–6.
Vaccine Dengue serotype component (per dose) Lot number
TDV-1 TDV-2 TDV-3 TDV-4
TDV* 2 × 104 PFU 5 × 104 PFU 1 × 105 PFU 3 × 105 PFU 00909
TDVH4 2 × 104 PFU 5 × 104 PFU 1 × 105 PFU 1 × 106 PFU P819001
0.1  TDV 2 × 103 PFU 5 × 103 PFU 1 × 104 PFU 3 × 104 PFU 00909
Placebo PBS 00709
* Formerly described as ‘high-dose formulation’ [13,14]. TDVs were formulated in vaccine diluent comprising 15% (w/v) trehalose, 1.1% (w/v) poloxamer 407 (Pluronic®
F127 and Lutrol® F127), 0.1% (v/v) human albumin (United States Pharmacopeia), 33% (v/v) phosphate buffered saline (PBS), and 67% (v/v) Dulbecco’s modiﬁed eagle medium.
PFU,  plaque forming units; TDV, tetravalent dengue vaccine formulation; TDVH4, TDV formulation containing three-fold higher TDV-4; 0.1 TDV, one-tenth dose TDV.
Table 2
Summary of participants’ demographic characteristics (full analysis set).
Characteristic Group 1 (n = 25) Group 2 (n = 25) Group 3 (n = 24) Group 4 (n = 21) Group 5 (n = 21) Group 6 (n = 24)
Gender (n (%))
Female 15 (60) 14 (56) 12 (50) 8 (38) 9 (43) 9 (38)
Male  10 (40) 11 (44) 12 (50) 13 (62) 12 (57) 15 (62)
Race  or ethnic group (n (%))
Asian 0 (0) 1 (4) 1 (4) 0 (0) 0 (0) 0 (0)
Black/African American 0 (0) 2 (8) 1 (4) 0 (0) 0 (0) 1 (4)
Hawaiian/Paciﬁc Islander 0 (0) 0 (0) 0 (0) 1 (5) 0 (0) 0 (0)
Hispanic/Latino 6 (24) 3 (12) 7 (29) 0 (0) 2 (10) 0 (0)
Other  2 (8) 0 (0) 1 (4) 0 (0) 0 (0) 0 (0)
White  17 (68) 19 (76) 14 (58) 20 (95) 19 (90) 23 (96)
Age  (years)
Median (range) 30.0 (19.0, 43.0) 27.0 (21.0, 44.0) 28.5 (20.0, 43.0) 31.0 (18.0, 41.0) 31.0 (18.0, 45.0) 33.0 (23.0, 43.0)
Weight  (kg)
Median (range) 72.4 (51.9, 96.2) 73.7 (59.0, 113.8) 75.9 (55.3, 108.8) 79.3 (55.3, 105.7) 76.9 (52.2, 104.8) 83.9 (51.2, 104.3)
Height  (m)
Median 1.73 (1.52, 1.86) 1.69 (1.57, 1.89) 1.72 (1.47, 1.88) 1.73 (1.61, 1.93) 1.73 (1.57, 1.93) 1.75 (1.57, 1.99)
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SBody  mass index (kg/m2)
Median (range) 25.30 (19.50, 28.90) 25.60 (19.40, 31.80) 2
Previous infection with one DENV provides long-lasting immu-
ity to the homologous serotype, but may  also lead to an increased
isk of severe disease upon secondary infection with a differ-
nt serotype [6–8]. Thus, dengue vaccine development has been
ocused on tetravalent vaccines that can simultaneously induce
mmunity to all four DENV [9].
The live tetravalent dengue vaccine candidate (TDV) used in
his study comprises an attenuated DENV-2 backbone (TDV-2) plus
ecombinant chimeric viruses for DENV-1, -3, and -4 generated
y substituting the structural surface antigen genes prM and E of
DV-2 with those of serotypes 1, 3, or 4 [10–12].
The primary objectives of this study were to compare the safety
f different dosage formulations and dose schedules of TDV, and
heir immunogenicity against DENV-1–4, in healthy adult vol-
nteers who were initially seronegative to common ﬂaviviruses,
ncluding dengue. TDV (previously described as the high-dose
able 3A
ummary of unsolicited AEs for the 30-day period following ﬁrst and second injections (s
Event Grade Group 1
(n = 25)
Following ﬁrst injection*
Participants with at least one AE (%) Any 21 (84) 
Participants with at least one related AE (%) Any 17 (68) 
Participants with AE leading to any action taken Any 11 (44) 
Participants with at least one SAE (%) Any 0 (0) 
Following second injection†
Participants with at least one AE (%) Any 15 (60) 
Participants with at least one related AE (%) Any 9 (36) 
Participants with AE leading to any action taken Any 7 (28) 
Participants with at least one SAE (%) – 0 (0) 
* Includes all AEs with onset on the day of or within 30 days after ﬁrst injection.
† Includes all AEs with onset on the day of or within 30 days after second injection.21.20, 33.70) 26.00 (20.70, 32.80) 25.00 (18.10, 32.00) 26.45 (19.50, 33.30)
formulation) was well tolerated and immunogenic when given
subcutaneously to ﬂavivirus-seronegative adults in a two-dose
schedule [13,14]. However, those studies also showed that the
TDV-4 vaccine component induced lower levels of seroconversion
than TDV-1–3. Interference among components of live attenuated
TDVs has been well documented, and adjusting relative concen-
trations may  be a means of maximizing responses to all four
DENV serotypes [15–17]. Hence, we evaluated a new formulation,
TDVH4, in which the dosage of TDV-4 was  increased three-fold,
to determine whether increasing the amount of TDV-4 would
increase the vaccine’s immunogenicity against this serotype. A one-
tenth dose was also evaluated to assess whether TDV’s safety or
immunogenicity would be impacted after the reductions in potency
that inevitably occur during vaccine storage. Lastly, we  evaluated
whether two  doses of TDV given in opposite arms on the same
day would affect its safety and immunogenicity, given that in
afety set).
Group 2
(n = 25)
Group 3
(n = 24)
Group 4
(n = 21)
Group 5
(n = 21)
Group 6
(n = 24)
19 (76) 21 (88) 16 (76) 17 (81) 18 (75)
16 (64) 17 (71) 14 (67) 11 (52) 14 (58)
10 (40) 9 (38) 6 (29) 12 (57) 10 (42)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
10 (42) 11 (48) 7 (37) 9 (56) 3 (14)
5 (21) 8 (35) 3 (16) 5 (31) 2 (10)
6 (25) 4 (17) 3 (16) 5 (31) 1 (5)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
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Table 3B
Summary of solicited injection site reactions following ﬁrst and second injections (Safety set).
Event Grade Group 1 (n = 25) Group 2 (n = 25) Group 3 (n = 24) Group 4 (n = 21) Group 5 (n = 21) Group 6 (n = 24)
Following ﬁrst study injection
Pain (Arm 1) 1 16 (64) 9 (38) 11 (46) 12 (57) 8 (42) 7 (29)
2  (0) 2 (8) 0 (0) 1 (5) 3 (16) 0 (0)
Pain  (Arm 2) 1 2 (8) 8 (33) 12 (50) 0 (0) 8 (42) –
2  0 (0) 2 (8) 0 (0) 0 (0) 3 (16) –
Itching  (Arm 1) 1 4 (16) 6 (25) 4 (17) 5 (24) 2 (11) 5 (21)
2  1 (4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Itching  (Arm 2) 1 0 (0) 3 (12) 7 (29) 0 (0) 0 (0) –
2  0 (0) 0 (0) 0 (0 0 (0) 0 (0) –
Erythema (Arm 1) 1 5 (20) 6 (25) 5 (21) 4 (19) 1 (5) 4 (17)
2  4 (16) 3 (12) 1 (4) 0 (0) 0 (0) 0 (0)
Erythema (Arm 2) 1 1 (4) 5 (21) 4 (17) 0 (0) 2 (11) –
2  0 (0) 2 (8) 4 (17) 0 (0) 0 (0) –
Edema  (Arm 1) 1 0 (0) 1 (4) 2 (8) 1 (5) 0 (0) 1 (4)
2  1 (4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Edema  (Arm 2) 1 0 (0) 2 (8) 0 (0) 0 (0) 0 (0) –
2  0 (0) 0 (0) 1 (4) 0 (0) 0 (0) –
Following second study injection
Pain (Arm 1) 1 13 (52) 1 (5) 6 (26) 6 (33) 5 (31) 6 (30)
2  0 (0) 0 (0) 0 (0) 0 (0) 3 (19) 0 (0)
Pain  (Arm 2) 1 – – – 0 (0) 6 (38) –
2  – – – 0 (0) 6 (38) –
Itching  (Arm 1) 1 5 (20) 1 (5) 4 (17) 1 (6) 0 (0) 3 (15)
2  1 (4) 0 (0) 0 (0) 0 (0) 1 (6) 0 (0)
Itching  (Arm 2) 1 – – – 0 (0) 1 (6) –
2  – – – 0 (0) 1 (6) –
Erythema (Arm 1) 1 5 (20) 0 (0) 4 (17) 1 (6) 2 (12) 2 (10)
2  4 (16) 1 (5) 3 (13) 0 (0) 0 (0) 0 (0)
Erythema (Arm 2) 1 – – – 0 (0) 1 (6) –
2  – – – 0 (0) 0 (0) –
Edema  (Arm 1) 1 4 (16) 0 (0) 1 (4) 0 (0) 0 (0) 0 (0)
2  0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Edema  (Arm 2) 1 – – – 0 (0) 0 (0) –
2  – – – 0 (0) 0 (0) –
For each reaction evaluated, the worst severity was  selected from all reactions recorded by diary within 14 days following the ﬁrst or the second vaccination. Grading of
injection site pain and itching was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 [19]. Erythema and edema were graded based
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3n  the widest area diameter according to the Food and Drug Administration (FDA) 
reclinical studies, multiple administrations at the same time
apidly generated protective, multivalent immune responses [18].
. Methods
.1. Study design and participants
This study was conducted at three centers in the United States
etween January 2012 and January 2014, in accordance with the
dinburgh revision of the Declaration of Helsinki, International
onference on Harmonization and Good Clinical Practice, and appli-
able national regulations. The protocol was approved by the local
nternal Review Boards (IRB), and registered on clinicaltrials.gov
CT01511250.
Participants were aged 18–45 years old at the time of screening,
n good general health, and seronegative for ﬂaviviruses (dengue,
est Nile, Japanese encephalitis, yellow fever), HIV-1, and hepatitis
 and C. They gave signed informed consent before enrolment. Key
xclusion criteria included seropositivity to any of the four dengue
erotypes, or to West Nile virus, a history of Japanese encephali-
is and/or yellow fever; previous vaccination against ﬂaviviruses; a
istory of recurring headaches; febrile illness (temperature ≥38 ◦C)
r moderate or severe acute illness or infection within 3 days of
osing; a history of signiﬁcant dermatologic disease in the last months; use within the previous 6 months of systemic corti-
osteroid therapy (≥0.5 mg/kg/day); and use of any non-steroidal
nti-inﬂammatory drugs, acetaminophen or antihistamines for the
 days immediately before each dose.ty Guidance [20].
This randomized, multicenter Phase 1b clinical study was con-
ducted in three stages and included six dosing regimen study
groups (Fig. 1). Eligible participants were enrolled into the study
and allocated sequentially to one of the three stages. Participants
in Stage I were randomized 1:1:1 to Groups 1, 2 or 3. After all
participants were enrolled in Stage I, participants in Stage II were
randomized 1:1 to Groups 4 and 5. Participants and investigators
were blinded to study treatment in Stages I and II. Stage III, which
started after all participants had been enrolled in Stage II, was open-
label as it comprised only one study group (Group 6).
A statistician who was  not involved in conducting the study
prepared list-based randomization schedules for Stages I and II
stratiﬁed by study site, using an appropriate blocking scheme to
ensure balance between study dose assignments.
2.2. Study treatments
Dosing schedules and different dose compositions used in
Groups 1–6 are summarized in Fig. 1 and Table 1. Participants in
Groups 1–3 received their ﬁrst dose (D1) on Day 0, comprising one
injection of either TDV or placebo in each arm; their second dose
(D2) was given on Day 90 as a single injection in one arm. Par-
ticipants in Groups 4 and 5 received one injection in each arm on
Day 0 (D1), and one injection in each arm on Day 90 (D2). Placebo
(phosphate-buffered saline, PBS) was  used in Stages I and II at
the appropriate time points to maintain the double-blind design
for safety and immunogenicity assessments. Group 6 participants
received a single injection in one arm on Day 0 (D1) and Day 90
R. Rupp et al. / Vaccine 33 (2015) 6351–6359 6355
F sis set
1
(
1
s
(
2
o
a
c
m
9
a
oig. 2. Seroconversion rates to each dengue serotype by treatment group (full analy
20.
D2). All participants were followed until their ﬁnal visit on Day
20.
Each 0.5 mL  dose of TDV (Table 1) or PBS was  administered by
ubcutaneous injection in the deltoid region; concomitant doses
when speciﬁed) were given in opposite arms at the same visit.
.3. Outcomes and assessments
Primary safety endpoints were the frequency and severity
f unsolicited and diary-recorded solicited (local and systemic)
dverse events (AE) after each injection.
The primary immunogenicity endpoints were rates of sero-
onversion to each of the DENV. A 50% focus reduction
icro-neutralization test (MNT), in which immunostained foci on
6-well plates are counted, was used to determine neutralizing
ntibodies titers MNT50. The MNT50 is the reciprocal of the last
bserved serum dilution that reduced the number of input viral). (A) Monovalent seroconversion over time; (B) multivalent seroconversion at Day
foci by 50% or greater. Seroconversion was deﬁned as an initially
seronegative participant who became seropositive, i.e. MNT50 ≥10
or a four-fold increase in MNT50 after injection [13].
Secondary endpoints were the incidence and duration of vaccine
viral RNA (detected in blood by qRT-PCR for each of the four TDV
components [13] on Days 0, 7, 9, 11, 14, 17, 21, 90, 97, and 104), and
geometric mean neutralizing MNT50 antibody titers (GMTs) to each
DENV serotype on Days 30, 90 and 120. Safety assessments also
included clinical laboratory evaluations (serum chemistry, hema-
tology and urinalysis) 7 and 14 days after each injection.
2.4. Statistical analysesThe Safety Set (SS) comprised all randomized participants who
received at least the ﬁrst study injection(s). The Full Analysis Set
(FAS) comprised all randomized participants who received at least
one study treatment and for whom valid pre-dosing and at least one
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Fig. 3. Neutralizing antibody responses to each dengu
alid post-dosing blood samples were received. The Per-Protocol
et (PPS) comprised all participants in the FAS who had no pre-
peciﬁed major protocol violations.
This was an exploratory study to assess the safety, tol-
rability, and immunogenicity of different schedules of TDV
ormulations in healthy adults, and was therefore not pow-
red to detect any differences between the treatment groups.
 sample size of approximately 136 participants was chosen
mpirically.
Safety data from the SS were summarized descriptively. Summ-
ries included solicited AEs occurring within the 14 days following
ach dose and unsolicited AEs with onset on or after D1 and within
0 days following D2. Missing/unknown severity was not imputed,
nd the most severe episode recorded was used regardless of the
umber of diary entries.
The FAS was analyzed for immunogenicity outcomes by study
roup. Seroconversion rates were calculated as percentages with
5% exact Clopper–Pearson conﬁdence intervals (CI) for each of the
our DENV and for multiple dengue serotypes. GMT  of dengue neu-
ralizing antibodies (DEN) to each serotype from MNT50 and their
5% CIs were calculated using log-transformed titers and presented
n exponentiated form. Seroconversion was also evaluated in the
PS as a sensitivity analysis.. Results
One hundred and forty participants were sequentially enrolled
nto Stages I–III and randomized to treatment with differentStudy Day
type by treatment group over time (full analysis set).
formulations, doses and schedules of TDV and/or placebo as shown
in Fig. 1. Of these, eight participants did not complete the ﬁnal
Day 120 visit: one participant (Group 2) was lost to follow-up; one
(Group 3) was withdrawn by the investigator due to joint pain on
Day 4; ﬁve withdrew consent after D1 (in Groups 4 and 5), and
one (Group 5) was withdrawn due to pregnancy after D1. The par-
ticipants’ baseline demographic characteristics are summarized in
Table 2; they were generally similar between groups.
3.1. Safety and reactogenicity
All vaccinations were generally well tolerated, and no serious
adverse events (SAEs) were reported during the study. The rates
of unsolicited AEs were similar among groups, with no trends
toward increased incidence with higher doses or increased TDV-
4, and the incidence decreased in all groups after the second dose
(Tables 3A–3C). The most common unsolicited AEs overall were
headache (in 52% of participants), fatigue (43%) and myalgia (29%;
Supplementary Table 1).
Pain was  the most commonly reported injection-site reaction.
After the ﬁrst dose, the solicited incidence ranged from 29 to 64%
across the study groups; severity was  mostly mild. The incidences
of pain, itching and erythema were higher in arms that received TDV
vaccines than in those that received placebo for Groups 1 and 4. No
meaningful increases in injection site reactions were observed with
the increased TDV-4 dose (Tables 3A–3C; comparing Groups 1 and
4). The most common solicited systemic AEs after either the ﬁrst
or second TDV administration were headache, fatigue and muscle
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Table  3C
Summary of Solicited systemic reactions within 14 days following ﬁrst and second injections (Safety set).
Event Grade Group 1 (n = 25) Group 2 (n = 25) Group 3 (n = 24) Group 4 (n = 21) Group 5 (n = 21) Group 6 (n = 24)
Following ﬁrst study injection
Fever 1 1 (4) 0 (0) 1 (4) 2 (10) 2 (11) 0 (0)
2  0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Headache 1  6 (24) 6 (25) 7 (29) 7 (33) 6 (32) 7 (29)
2  4 (16) 5 (21) 3 (12) 1 (5) 4 (21) 2 (8)
3  1 (4) 0 (0) 0 (0) 0 (0) 1 (5) 1 (4)
Muscle  pain 1 8 (32) 5 (21) 7 (29) 3 (14) 6 (32) 4 (17)
2  0 (0) 2 (8) 1 (4) 0 (0) 1 (5) 0 (0)
3  0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 0 (0)
Joint  pain 1 3 (12) 3 (12) 5 (21) 0 (0) 2 (11) 2 (8)
2  1 (4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Eye  pain 1 1 (4) 2 (8) 2 (8) 4 (19) 4 (21) 3 (12)
2  2 (8) 0 (0) 0 (0) 1 (5) 0 (0) 0 (0)
Photophobia 1  0 (0) 3 (12) 2 (8) 3 (14) 3 (16) 4 (17)
2  2 (8) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Fatigue 1  6 (24) 7 (29) 8 (33) 9 (43) 3 (16) 4 (17)
2  3 (12) 3 (12) 2 (8) 1 (5) 6 (32) 1 (4)
3  1 (4) 0 (0) 0 (0) 0 (0) 0 (0) 1 (4)
Rash  anywhere on
body
1 5 (20) 2 (8) 1 (4) 3 (14) 3 (16) 1 (4)
2  0 (0) 1 (4) 0 (0) 0 (0) 0 (0) 0 (0)
Nausea 1  1 (4) 3 (12) 1 (4) 3 (14) 4 (21) 1 (4)
2  1 (4) 0 (0) 0 (0) 1 (5) 0 (0) 1 (4)
Vomiting 1  0 (0) 0 (0) 0 (0) 1 (5) 0 (0) 0 (0)
2  0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Following second study injection
Fever 1 0 (0) 0 (0) 1 (4) 1 (6) 1 (6) 0 (0)
2  0 (0) 1 (5) 0 (0) 0 (0) 0 (0) 0 (0)
Headache 1  5 (20) 1 (5) 3 (13) 3 (17) 2 (12) 2 (10)
2  4 (16) 3 (14) 2 (9) 1 (6) 4 (25) 1 (5)
3  1 (4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Muscle  pain 1 1 (4) 2 (9) 1 (4) 1 (6) 3 (19) 1 (5)
2  2 (8) 1 (5) 0 (0) 0 (0) 1 (6) 0 (0)
3  0 (0) 0 (0) 0 (0) 1 (6) 1 (6) 0 (0)
Joint  pain 1 0 (0) 1 (5) 0 (0) 0 (0) 1 (6) 2 (10)
2  0 (0) 1 (5) 0 (0) 1 (6) 1 (6) 0 (0)
3  0 (0) 0 (0) 0 (0) 0 (0) 1 (6) 0 (0)
Eye  pain 1 0 (0) 0 (0) 0 (0) 1 (6) 0 (0) 0 (0)
2  1 (4) 2 (9) 0 (0) 0 (0) 0 (0) 0 (0)
3  0 (0) 0 (0) 0 (0) 0 (0) 1 (6) 0 (0)
Photophobia 1  1 (4) 0 (0) 0 (0) 0 (0) 2 (12) 1 (5)
2  1 (4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
3  0 (0) 0 (0) 0 (0) 0 (0) 1 (6) 0 (0)
Fatigue 1  5 (20) 1 (5) 1 (4) 1 (6) 2 (12) 1 (5)
2  3 (12) 2 (9) 1 (4) 1 (6) 3 (19) 0 (0)
Rash  anywhere on
body
1 0 (0) 0 (0) 1 (4) 0 (0) 1 (6) 0 (0)
2  0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Nausea 1  1 (4) 1 (5) 1 (4) 0 (0) 1 (6) 0 (0)
2  0 (0) 0 (0) 0 (0) 0 (0) 1 (6) 0 (0)
Vomiting 1  0 (0) 0 (0) 1 (4) 0 (0) 0 (0) 0 (0)
2  0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
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vor each reaction evaluated, the worst severity was  selected from all reactions recor
raded  using the Common Terminology Criteria for Adverse Events (CTCAE) Version
s  ‘muscle pain’, ‘sensitivity to light’ and ‘tiredness’..
ain; most cases were mild and the reported incidences decreased
fter the second dose.
Three participants did not receive the second dose after repor-
ing treatment-related AEs. One participant in Group 5 had severe
uscle pain and joint pain on Day 9, and reported feeling fever-
sh and having chills on that day. The participant received a 3-day
ourse of paracetamol and these AEs resolved within 2 days. One
articipant in Group 6 had non-severe joint swelling and joint pain
n Day 16; the participant received a 6-day course of ibuprofen and
hese AEs resolved within 8 days. Another participant in Group 6
ad non-serious photophobia on Day 15, which resolved within 4
ays. All three participants continued with protocol safety evalu-
tions and immunogenicity assays until the end of the study and
ere included in the SS and FAS (Fig. 1).
No clinically signiﬁcant changes from baseline were observed in
ematology, chemistry or vital signs at any of the scheduled study
isits (data not shown).y diary within 14 days following the ﬁrst or the second vaccination. Reactions were
[19]. Myalgia, photophobia and fatigue were, respectively, listed on the diary cards
3.2. Immunogenicity
Seroconversion rates over time are summarized by serotype in
Fig. 2A. As seroconversion results for the PPS were essentially the
same as for the FAS, only the latter are shown. Seroconversion to
DENV-2 was >90% in all groups at all time points. Seroconversion
rates to DENV-1 and DENV-3 were >80% in all groups at Day 120, the
primary immunogenicity endpoint, after two doses. Seroconver-
sion rates for DENV-4 were lower than for the other serotypes with
all dosing schedules. The highest DENV-4 seroconversion rates at
all time points were achieved using the TDVH4 formula—in Groups
4 and 5, more than 70% of participants had seroconverted to DENV-
4 at Day 120. However, the higher dose of TDV4 in Groups 4 and 5
resulted in slightly lower rates of seroconversion to DENV-1.
The percentages of participants who  seroconverted to multi-
ple dengue serotypes 30 days after the second dose (Day 120)
are shown in Fig. 2B. More than 80% of participants in all groups
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eroconverted to three or more serotypes at Day 120. In groups that
eceived the increased dose of TDV-4 (Groups 4 and 5), 68% and 76%
f participants, respectively, seroconverted to all four DENV. How-
ver, tetravalent seroconversion rates in these groups were only
arginally higher than their comparator, Group 1 (which received
DV), in which 60% of the participants seroconverted to all four
erotypes. Giving an extra dose in the alternate arm on Day 0 (Group
 compared to Group 1) did not improve seroconversion rates to
ither individual (Fig. 2A) or multiple dengue serotypes (Fig. 2B).
ikewise, giving extra doses in the alternate arm on both Day 0 and
ay 90 (as given in Group 5) did not meaningfully enhance sero-
onversion rates to individual serotypes at Day 120 compared with
 two-dose schedule (compare with Group 4; Fig. 2A).
GMTs of dengue neutralizing antibodies over 120 days are
hown in Fig. 3. Substantial increases from baseline were observed
or DEN-1, DEN-2 and DEN-3 at Day 30 and at all subsequent
ime points. GMT  increases for DENV-4 were lower. DEN-2 GMT
ncreases were the greatest at all time points in all groups, and
id not vary substantially according to vaccine dose or schedule. A
ouble dose at Day 0 had no meaningful impact on GMTs of any
erotype.
Few differences in DEN-2 and DEN-3 GMTs were seen between
he different groups. Groups 4 and 5 (higher TDV-4 titers) showed a
rend toward higher DEN-4 GMTs. However, increasing the relative
oncentration of TDV-4 negatively impacted DEN-1 GMTs (Groups
 and 5 versus Group 1).
Reducing the overall TDV dose by a factor of ten had little impact
n the GMTs for DEN-1 or DEN2 (compare Group 1 with Group 6),
lightly decreased GMTs for DEN-3, and slightly increased DENV-4
MTs versus TDV after the ﬁrst dose.
.3. Vaccine viral RNA
TDV RNA was detected for TDV-2 in all groups (Supplementary
able 2). For Groups 2 and 5, the highest proportions of participants
ith detectable TDV RNA were observed on Day 9 (72% and 61% of
articipants, respectively); in the other groups the highest propor-
ions were observed on Day 11 (61–75% of participants). TDV-2
iral RNA was not detected after Day 17 except in one participant
n Group 4 at Day 21.
Single participants had detectable TDV-3 RNA on Days 9 and 11
n Group 4, and on Day 90 in Group 2. TDV-4 RNA was observed on
ay 11 in one participant in Group 4. TDV viral RNA replication was
ot detected in any participants following the second vaccination.
o association between TDV virus replication and AE incidence was
bserved.
. Discussion
All TDV formulations, doses and dosing schedules were well tol-
rated in this US-based cohort of healthy, ﬂavivirus-naive adults.
either simultaneous administration of two doses of TDV, nor use
f the TDVH4 formulation, led to higher incidences of treatment-
elated unsolicited AEs. No SAEs were reported. Overall, the
ncidence and severity of solicited AEs were low, similar among
osing schedules, and consistent with previous ﬁndings [13,14].
ild injection site pain, headache, fatigue and myalgia were the
ost common AEs.
This study was designed without a placebo control group
ecause the goal was to compare alternate vaccine components,
ose forms and schedules to those previously characterized for TDV
n Phase 1 studies [13,14]. In several groups, placebo was admin-
stered in the alternate arm, allowing comparisons of injection site
eactions between placebo and vaccine. While the TDV, TDVH4
nd one-tenth TDV formulations led to higher incidences of pain, (2015) 6351–6359
itching and erythema than placebo, no clinically relevant differ-
ences in injection site AEs were seen between them. A study
weakness is the relatively small number of participants in each
group. However, the safety and immunogenicity ﬁndings are simi-
lar to those observed previously for TDV [13,14].
The highest serotype-speciﬁc seroconversion rates and
strongest neutralizing antibody responses were elicited by
TDV-2, the backbone vaccine virus, followed by TDV-1 and -3;
TDV-4 generated the lowest responses. Nevertheless, 60% of
participants who  received TDV at Days 0 and 90 (Group 1) had
seroconverted to DEN-4 by Day 120; this proportion increased
to 68% and 76% of groups that received the TDVH4 formula-
tion. Seroconversion rates to DEN-1–3 were high (>80% of all
groups seroconverted to three or more serotypes after two doses)
and were not meaningfully impacted by formulation or dosing
schedule. After GMTs of neutralizing antibodies peaked at Day
30, they waned over the next 2 months. A second dose at Day 90
increased DEN-1, -3 and -4 GMTs in most groups, but had no effect
on DEN-2 GMTs. However, the second dose did not meaningfully
increase neutralizing antibody GMTs to higher levels than those
observed at Day 30 for any of the DENV.
Increasing the concentration of TDV-4 slightly increased TDV’s
DENV-4 immunogenicity in terms of seroconversion rates and
GMTs, at the expense of DENV-1 seroconversion rates and neutral-
izing antibodies. These data suggest that TDV-1 immunogenicity
may  be sensitive to competition from TDV-4. A three- or four-dose
schedule did not appear to enhance immunogenicity compared
with a two-dose schedule.
Diluting TDV ten-fold had little impact on GMTs to any serotype.
We recognize that dilution only approximates the effects of
reductions in potency with storage; inactive viral products may
(negatively or positively) affect immunogenicity. Nevertheless, the
data suggest that reductions in overall titer of the live attenuated
vaccine to the extent that might occur during storage should not
have any meaningful effect on clinical immunogenicity.
The rationale for simultaneous administration of one TDV dose
in opposite arms was  based on (i) the hypothesis that this could
activate immune cells and antigen-presenting cells that trafﬁc
to two  different sets of lymph nodes, thereby reducing interfer-
ence between the TDV components and increasing immunogenicity
[18]; (ii) potential acceleration of the seroconversion rate to mul-
tiple dengue serotypes [18], and (iii) improvement of vaccine
compliance by reducing the number of vaccination visits. In this
study, multiple administrations on the same day did not improve
DEN-4 GMTs or seroconversion to multiple serotypes.
In conclusion, all TDV formulations, doses and dosing schedules
were well tolerated and immunogenic in healthy adults who  had
not previously been exposed to dengue. These results with alter-
native formulations and schedules can inform protocols for future
clinical trials of the candidate TDV, including the assessment of a
single dose schedule.
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